References
- Hadjivasiliou A. Evaluate pharma: orphan drug report 2014. [cited 2016 Jan 8]. Available from: http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf
- Emanuel EJ. The solution to drug prices. The New York Times. 2015 Sep 9.
- Sheldon T. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ. 2012;345:e5461.
- Hyry HI, Stern AD, Cox TM, et al. Limits on use of health economic assessments for rare diseases. QJM. 2014;107(3):241–245.
- An act to amend the federal food, drug, and cosmetic act to facilitate the development of drugs for rare diseases and conditions, and for other purposes; 1983 Jan 4. Available from: https://history.nih.gov/research/downloads/PL97-414.pdf
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. [cited 2016 Jan 8]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf
- United States Congress. Orphan drug reauthorization: hearing before the subcommittee on health and the environment of the committee on energy and commerce, house of representatives, one hundred third congress, second session on h.r. 4160, a bill to amend the federal food, drug and cosmetic act, the public health service act, and the orphan drug act to revise the provisions of such acts relating to orphan drugs. Washington (DC): US Government Printing Office; 1994.
- European Medicines Agency, Orphan designation. [cited 2016 Jan 8]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products, Article 4(2)(a). [cited 2016 Jan 8]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products, Article 8(2). [cited 2016 Jan 8]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf
- Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products, Article 8(1). [cited 2016 Jan 8]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf
- European Medicines Agency. Record number of medicines for rare diseases recommended for approval in 2014. 2015 Jan. [cited 2016 Jan 8]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002247.jsp&mid=WC0b01ac058004d5c1
- Lists of medicinal products for rare diseases in Europe. Orphanet Report Series, Orphan Drugs collection. Oct 2015. [cited 2015 Dec 1]. Available form: http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf
- Kesselheim AS, Myers JA, Solomon DH, et al. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE. 2012 February;7(2):e31894.
- Peplow T. At the junction of orphan drugs and personalized medicine. Total Orphan Drugs. 2013 Nov 29. [Internet]. [cited 2016 Jan 8]. Available from: http://www.orphan-drugs.org/2013/11/29/junction-orphan-drugs-personalized-medicine/
- Vertex. Vertex receives European approval for KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people with a specific genetic mutation (G551D); 2012 July 27. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=696069
- Ledford H. CRISPR, the disruptor. Nature. 2015;522(7554):20–24.
- European Medicines Agency. Medicines for rare diseases. [cited 2016 Jan 8]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000034.jsp
- Ekins S, Williams AJ, Krasowski MD, et al. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today. 2011 Apr;16(7–8):298–310.
- Simoens S, Cassiman D, Dooms M, et al. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72:1437–1443.
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
- Roos J, Hyry H, Cox TM. Orphan drug pricing may warrant a competition law investigation. BMJ. 2010;341:c6471.
- Ford J. Pricing of life-saving drugs is put under the microscope. Financial Times. 2015 Aug 17.
- Curran AV, Schott CH, Leiter AB, et al. 340B program: orphan drug exception—a timeline of PhRMA’s legal challenge to HRSA’s final rule [Internet]. [cited 2016 Jan 8]. Available from: http://www.lexology.com/library/detail.aspx?g=7e2d3c7a-8f43-4833-b939-ffb41d64036f
- Jain D, Darrow JJ. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India. Health Matrix Clevel. 2013;23(2):425–457.
- Rosenberg ST. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil. Dev World Bioeth. 2014;14(2):83–91.
- Canada Patented Medicine Prices Review Board. Mandate and jurisdiction. [cited 2016 Jan 8]. Available from: http://pmprb-cepmb.gc.ca/about-us/mandate-and-jurisdiction
- 2012/C 326/01 consolidated versions of the treaty on European Union and the treaty on the functioning of the European Union, Article 118. [cited 2016 Jan 8]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:C:2012:326:FULL&from=EN
- Human Rights. EUR-Lex. [cited 2016 Jan 8]. http://eur-lex.europa.eu/summary/chapter/human_rights.html?root_default=SUM_1_CODED=13
- Trevor Little. Plain packaging battle escalates as WTO prepares for hearings on challenges to Australian regime [Internet]. World Treademark Review; 26 May 2015. [cited 2016 Jan 8]. Available from: http://www.worldtrademarkreview.com/Blog/detail.aspx?g=aee2b117-e8b5-4144-91e2-444949613101
- Hyry HI, Manuel J, Cox TM, et al. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015;10:100.
- Garber AM, McClellan MB. Satisfaction guaranteed–”payment by results” for biologic agents. N Engl J Med. 2007;357(16):1575–1577.
- Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015 Dec 31;373(27):2595–2597.